Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ruby Wu"'
Publikováno v:
Health and Quality of Life Outcomes, Vol 17, Iss 1, Pp 1-6 (2019)
Abstract Background Cancer treatments are associated with a multitude of adverse events (AEs). While both nurses and physicians are involved in patient care delivery and AE assessment, very few studies have examined the differences between nurses’
Externí odkaz:
https://doaj.org/article/7bf5334fb12e48bf9963b2a78b751632
Autor:
Erin Honan, Melissa K. Accordino, Ruby Wu, Kathleen Fenn, Tizita Z. Zeleke, Kevin Kalinsky, Cody Chiuzan, Qingfei Pan, Dawn L. Hershman, Jose Silva, Jiyang Yu, Matthew Maurer, Meghna S. Trivedi, Katherin D Crew, Maika Onishi, Sean A. Kelly
Publikováno v:
Cancer Research. 80:P1-19
Background:HDAC6, a cytoplasmic histone deacetylase, impacts cell viability by influencing protein metabolism, microtubule dynamics, and chaperone function. ACY-1215 is an orally active, selective HDAC6 inhibitor. Preclinical studies have demonstrate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1bc3db3a63fee6cdfca548887c81466
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-27
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-27
Publikováno v:
Health and Quality of Life Outcomes, Vol 17, Iss 1, Pp 1-6 (2019)
Health and Quality of Life Outcomes
Health and Quality of Life Outcomes
Background Cancer treatments are associated with a multitude of adverse events (AEs). While both nurses and physicians are involved in patient care delivery and AE assessment, very few studies have examined the differences between nurses’ and physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e8efa45eec99ca1de5a5dc131c3567d
http://link.springer.com/article/10.1186/s12955-019-1210-1
http://link.springer.com/article/10.1186/s12955-019-1210-1
Autor:
Tizita Z. Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J. Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S. Trivedi, Melissa Accordino, Katherine D. Crew, Dawn L. Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin Kalinsky, Jiyang Yu, Jose Silva
Publikováno v:
Nature cancer.
Inhibiting individual histone deacetylase (HDAC) is emerging as well-tolerated anticancer strategy compared with pan-HDAC inhibitors. Through preclinical studies, we demonstrated that the sensitivity to the leading HDAC6 inhibitor (HDAC6i) ricolinsta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4bb501f66ef195b4fea1214651717ba
https://pubmed.ncbi.nlm.nih.gov/36585452
https://pubmed.ncbi.nlm.nih.gov/36585452
Autor:
Tizita Z. Zeleke, Matthew Maurer, Meghna S. Trivedi, Ruby Wu, Katherine D. Crew, Mariano J. Alvarez, Pei Ling Chia, Sean A. Kelly, Qingfei Pan, Dawn L. Hershman, Min Yang, Andrea Califano, Jiyang Yu, Partha Mukhopadhyay, Melissa Kate Accordino, Maika Onishi, Cody Chiuzan, Erin Honan, Kathleen Fenn, Jose Silva, Simon Jones, Kevin Kalinsky
Publikováno v:
Cancer Research. 81:645-645
Despite the anticancer activity of pan-histone deacetylase (HDAC) inhibitors, their clinical use has been limited due to toxicity. However, the development of more specific inhibitors that selectively inhibit individual HDACs is emerging as a novel a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49f440092b90d67f34cbca89e882bc5e
https://doi.org/10.1158/1538-7445.am2021-645
https://doi.org/10.1158/1538-7445.am2021-645